Johnson & Johnson annual cash and equivalents
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Johnson & Johnson Cash & Equivalents Growth & History (JNJ)
Johnson & Johnson's cash and equivalents was $19.71B for fiscal 2025.
View full Johnson & Johnson company overviewJohnson & Johnson annual cash and equivalents history
| Fiscal year | Period ended | Cash and equivalents | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-28 | $19.71B | −$4.40B | −18.24% |
| 2024 | 2024-12-29 | $24.11B | $2.25B | +10.27% |
| 2023 | 2023-12-31 | $21.86B | $8.97B | +69.59% |
| 2022 | 2023-01-01 | $12.89B | −$1.60B | −11.03% |
| 2021 | 2022-01-02 | $14.49B | $502.0M | +3.59% |
| 2020 | 2021-01-04 | $13.98B | −$3.32B | −19.19% |
| 2019 | 2019-12-29 | $17.30B | −$802.0M | −4.43% |
| 2018 | 2018-12-30 | $18.11B | $283.0M | +1.59% |
| 2017 | 2017-12-31 | $17.82B | −$1.15B | −6.05% |
| 2016 | 2017-01-01 | $18.97B | $5.24B | +38.16% |
| 2015 | 2016-01-03 | $13.73B | −$791.0M | −5.45% |
| 2014 | 2014-12-28 | $14.52B | −$6.40B | −30.60% |
| 2013 | 2013-12-29 | $20.93B | $6.02B | +40.35% |
| 2012 | 2012-12-30 | $14.91B | −$9.63B | −39.24% |
| 2011 | 2012-01-01 | $24.54B | $5.19B | +26.80% |
| 2010 | 2011-01-02 | $19.36B | $3.54B | +22.42% |
| 2009 | 2010-01-03 | $15.81B | $5.04B | +46.82% |
| 2008 | 2008-12-28 | $10.77B | $3.00B | +38.58% |
| 2007 | 2007-12-30 | $7.77B | — | — |
Johnson & Johnson quarterly cash and equivalents
Q4.08
Q2.09
Q3.09
Q4.09
Q1.10
Q2.10
Q3.10
Q4.10
Q1.11
Q2.11
Q3.11
Q4.11
Q1.12
Q2.12
Q3.12
Q4.12
Q1.13
Q2.13
Q3.13
Q4.13
Q1.14
Q2.14
Q3.14
Q4.14
Q1.15
Q2.15
Q3.15
Q4.15
Q1.16
Q2.16
Q3.16
Q4.16
Q1.17
Q2.17
Q3.17
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
As of Jan 3, 2021
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Cash and equivalents | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-28 | $20.42B | $1.84B | +9.93% |
| Q1 2026 | 2026-03-29 | $21.69B | −$16.79B | −43.63% |
| Q4 2025 | 2025-12-28 | $19.71B | −$4.40B | −18.24% |
| Q3 2025 | 2025-09-28 | $18.23B | −$1.75B | −8.75% |
| Q2 2025 | 2025-06-29 | $18.58B | −$6.30B | −25.33% |
| Q1 2025 | 2025-03-30 | $38.47B | $13.00B | +51.04% |
| Q4 2024 | 2024-12-29 | $24.11B | $2.25B | +10.27% |
| Q3 2024 | 2024-09-29 | $19.98B | $252.0M | +1.28% |
| Q2 2024 | 2024-06-30 | $24.88B | $3.69B | +17.44% |
| Q1 2024 | 2024-03-31 | $25.47B | $6.30B | +32.88% |
| Q4 2023 | 2023-12-31 | $21.86B | $8.97B | +69.59% |
| Q3 2023 | 2023-10-01 | $19.73B | $8.37B | +73.74% |
| Q2 2023 | 2023-07-02 | $21.18B | $10.20B | +92.87% |
| Q1 2023 | 2023-04-02 | $19.17B | $8.71B | +83.22% |
| Q4 2022 | 2023-01-01 | $12.89B | −$1.60B | −11.03% |
| Q3 2022 | 2022-10-02 | $11.36B | −$6.25B | −35.50% |
| Q2 2022 | 2022-07-03 | $10.98B | −$3.35B | −23.37% |
| Q1 2022 | 2022-04-03 | $10.46B | −$2.21B | −17.43% |
| Q4 2021 | 2022-01-02 | $14.49B | — | — |
| Q3 2021 | 2021-10-03 | $17.60B | −$1.36B | −7.18% |
| Q2 2021 | 2021-07-04 | $14.33B | $3.16B | +28.26% |
| Q1 2021 | 2021-04-04 | $12.67B | −$2.86B | −18.41% |
| Q4 2020 | 2021-01-04 | $13.98B | −$3.32B | −19.19% |
| As of Jan 3, 2021 | 2021-01-03 | $13.98B | −$3.32B | −19.19% |
| Q3 2020 | 2020-09-27 | $18.96B | $2.72B | +16.71% |
| Q2 2020 | 2020-06-28 | $11.17B | −$3.20B | −22.27% |
| Q1 2020 | 2020-03-29 | $15.53B | $796.0M | +5.40% |
| Q4 2019 | 2019-12-29 | $17.30B | −$802.0M | −4.43% |
| Q3 2019 | 2019-09-29 | $16.25B | $193.0M | +1.20% |
| Q2 2019 | 2019-06-30 | $14.38B | −$3.19B | −18.17% |
| Q1 2019 | 2019-03-31 | $14.73B | $95.0M | +0.65% |
| Q4 2018 | 2018-12-30 | $18.11B | $283.0M | +1.59% |
| Q3 2018 | 2018-09-30 | $16.06B | $335.0M | +2.13% |
| Q2 2018 | 2018-07-01 | $17.57B | $4.97B | +39.46% |
| Q1 2018 | 2018-04-01 | $14.64B | −$6.27B | −29.99% |
| Q4 2017 | 2017-12-31 | $17.82B | −$1.15B | −6.05% |
| Q3 2017 | 2017-10-01 | $15.72B | −$2.48B | −13.64% |
| Q2 2017 | 2017-07-02 | $12.60B | −$6.04B | −32.41% |
| Q1 2017 | 2017-04-02 | $20.91B | $7.05B | +50.85% |
| Q4 2016 | 2017-01-01 | $18.97B | $5.24B | +38.16% |
| Q3 2016 | 2016-10-02 | $18.20B | $4.57B | +33.48% |
| Q2 2016 | 2016-07-03 | $18.64B | $8.00B | +75.20% |
| Q1 2016 | 2016-04-03 | $13.86B | $1.87B | +15.62% |
| Q4 2015 | 2016-01-03 | $13.73B | −$791.0M | −5.45% |
| Q3 2015 | 2015-09-27 | $13.64B | −$179.0M | −1.30% |
| Q2 2015 | 2015-06-28 | $10.64B | −$3.60B | −25.27% |
| Q1 2015 | 2015-03-29 | $11.99B | −$7.73B | −39.22% |
| Q4 2014 | 2014-12-28 | $14.52B | −$6.40B | −30.60% |
| Q3 2014 | 2014-09-28 | $13.82B | −$3.39B | −19.68% |
| Q2 2014 | 2014-06-29 | $14.24B | −$3.07B | −17.74% |
| Q1 2014 | 2014-03-30 | $19.72B | $4.87B | +32.76% |
| Q4 2013 | 2013-12-29 | $20.93B | $6.02B | +40.35% |
| Q3 2013 | 2013-09-29 | $17.20B | $1.72B | +11.09% |
| Q2 2013 | 2013-06-30 | $17.31B | $3.27B | +23.25% |
| Q1 2013 | 2013-03-31 | $14.86B | −$15.41B | −50.92% |
| Q4 2012 | 2012-12-30 | $14.91B | −$9.63B | −39.24% |
| Q3 2012 | 2012-09-30 | $15.49B | −$131.0M | −0.84% |
| Q2 2012 | 2012-07-01 | $14.04B | −$932.0M | −6.22% |
| Q1 2012 | 2012-04-01 | $30.27B | $7.91B | +35.39% |
| Q4 2011 | 2012-01-01 | $24.54B | $5.19B | +26.80% |
| Q3 2011 | 2011-10-02 | $15.62B | $1.28B | +8.92% |
| Q2 2011 | 2011-07-03 | $14.97B | $2.26B | +17.78% |
| Q1 2011 | 2011-04-03 | $22.36B | $8.61B | +62.67% |
| Q4 2010 | 2011-01-02 | $19.36B | $3.54B | +22.42% |
| Q3 2010 | 2010-10-03 | $14.34B | $2.48B | +20.93% |
| Q2 2010 | 2010-07-04 | $12.71B | $1.03B | +8.79% |
| Q1 2010 | 2010-04-04 | $13.74B | — | — |
| Q4 2009 | 2010-01-03 | $15.81B | $5.04B | +46.82% |
| Q3 2009 | 2009-09-27 | $11.86B | — | — |
| Q2 2009 | 2009-06-28 | $11.69B | — | — |
| Q4 2008 | 2008-12-28 | $10.77B | — | — |
Johnson & Johnson cash and equivalents trends
Over the last five fiscal years, Johnson & Johnson's cash and equivalents increased from $13.98B to $19.71B, a change of $5.72B. The latest reported quarter, Q2 2026, shows $20.42B.
About the metric
What cash and equivalents mean
Cash and cash equivalents, often described as cash on hand, are highly liquid resources available for near-term obligations, investment, acquisitions, debt repayment, dividends, or share repurchases. This measure does not include short-term investments reported separately.
Calculation and source
Reported cash and equivalents
TickerStat standardizes cash and cash equivalents reported on the balance sheet. Restricted cash is included only when the company reports it within the selected consolidated cash concept. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Johnson & Johnson source filings ↗Community posts
J&J reports surgery-comparator benefit for Erleada in prostate cancer
Johnson & Johnson ($JNJ) reported new PROTEUS substudy results comparing Erleada plus hormone therapy before and after prostate surgery with surgery alone. Among 408 patients with high-risk localized or locally advanced disease, the regimen ...
J&J reports early prostate-cancer responses for experimental oral drug
Johnson & Johnson ($JNJ) disclosed early results for oral JNJ-6143 in heavily pretreated advanced prostate cancer. Among 31 evaluable patients receiving 50 milligrams, 77% achieved at least a 50% PSA decline. Confirmed tumor responses occur ...
Carvykti follow-up finds half of a small cohort progression-free at five years
Johnson & Johnson ($JNJ) and Legend Biotech ($LEGN) reported five-year follow-up from 20 patients in the Phase 2 CARTITUDE-2 Cohort A study of Carvykti. Ten remained alive without disease progression or further anti-myeloma treatment after ...
Johnson & Johnson says Tremfya meets axial psoriatic-arthritis trial goals
Johnson & Johnson ($JNJ) said Tremfya met the primary and key secondary endpoints in STAR, a randomized, double-blind Phase 4 study in patients with axial manifestations of psoriatic arthritis. The company reported improvement over placebo ...
Apollo reportedly nears $20 billion talks for J&J orthopedics business
Apollo ($APO) is in talks to acquire Johnson & Johnson’s ($JNJ) DePuy Synthes orthopedics business in a transaction that could be worth around $20 billion, Reuters reported, citing Bloomberg. The unit generated approximately $9.3 billion in ...
